arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

iBio, Inc.

IBIO
$1.42 ▲ +0.03 (+1.80%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
64 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

iBio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $169.8M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -8.5%
FCF / Share $-0.05
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

64-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-5.72M
↓ -43.4%
Operating Margin Operating profit as % of sales
-261.5%
↑ +45.9%
FCF / Share Free cash flow per share
$-0.05
↑ +12.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
7
Financial Health
14
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 64 quarters